nach oben

European Journal of Clinical Microbiology & Infectious Diseases

Erschienen in:

Open Access 25.07.2017 | Original Article

Evaluation of the Carba NP test for carbapenemase detection in Enterobacteriaceae, Pseudomonas spp. and Acinetobacter spp., and its practical use in the routine work of a national reference laboratory for susceptibility testing

verfasst von: E. Literacka, M. Herda, A. Baraniak, D. Żabicka, W. Hryniewicz, A. Skoczyńska, M. Gniadkowski

Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases | Ausgabe 11/2017

Abstract

The aim of this study was to evaluate the Carba NP test (and CarbAcineto) for the detection of carbapenemases in Enterobacteriaceae, Pseudomonas spp. and Acinetobacter spp., and to assess its usefulness in the routine work of the National Reference Centre for Susceptibility Testing (NRCST) in Poland. The evaluation of the Carba NP/CarbAcineto tests was carried out on a group of 81 Enterobacteriaceae, Pseudomonas spp. and Acinetobacter spp. isolates producing KPC-, NDM-, VIM-, IMP- or OXA-48, -23, -24/40, -58-type carbapenemases, and on 26 carbapenemase-negative strains cultivated on a broad panel of microbiological media. Subsequently, the performance of the Carba NP/CarbAcineto tests was assessed on 1282 isolates of Enterobacteriaceae, Pseudomonas spp. and Acinetobacter spp. from Polish hospitals, submitted to the NRCST during a 9-month period in 2014. The Carba NP/CarbAcineto results were compared with other phenotypic tests and/or polymerase chain reaction (PCR). The impact of the media on the results of the Carba NP/CarbAcineto tests was observed, with the Columbia blood agar yielding the highest sensitivity and clarity of the results. Furthermore, the Carba NP/CarbAcineto tests were included in the NRCST routine procedure for carbapenemase identification. The sensitivity and specificity of the Carba NP test were 95.8% and 93.3%, respectively, for Enterobacteriaceae, and 97.5% and 99.0%, respectively, for Pseudomonas spp. The sensitivity of the CarbAcineto test for Acinetobacter spp. was 88.9%. This study confirmed the usefulness of the Carba NP/CarbAcineto tests for the rapid detection of various types of carbapenemases.

Introduction

The dynamic spread of carbapenemase-producing Enterobacteriaceae, Pseudomonas spp. and Acinetobacter spp. has been observed all over the world in recent years. The predominant carbapenemases include β-lactamases of the Ambler class A (KPCs), metallo-β-lactamases (MBLs) of the class B (VIMs, IMPs, NDMs) and carbapenem-hydrolysing oxacillinases of the class D (OXA-23, OXA-24/40, OXA-48 or OXA-58 types) [1‐9]. Carbapenemase producers notoriously exhibit multidrug resistance phenotypes, making treatment of infections extremely difficult [10‐13]. Therefore, quick, unambiguous, easy and cheap identification of carbapenemase-producing bacteria has been one of the priorities of modern clinical microbiology. The biochemical Carba NP test for Enterobacteriaceae and Pseudomonas spp., and its variant CarbAcineto for Acinetobacter spp., were proposed to address this challenge in 2012 and 2014, respectively [1, 14, 15]. Both tests were reported to have high specificity and sensitivity for all of the major carbapenemase types [1, 14, 15]; however, it was shown that, for some enzymes, the sensitivity relies strongly on the type of microbial medium used for bacteria cultivation [16‐18]. The original Carba NP test was soon followed by modified variants, and has been commercialised [19‐26].

The aim of this study was to evaluate the Carba NP and CarbAcineto tests for the detection of carbapenemase-producing Enterobacteriaceae, Pseudomonas spp. and Acinetobacter spp. cultivated on different media. Moreover, the Carba NP/CarbAcineto tests were assessed in the routine diagnostics of carbapenemase producers conducted by the National Reference Centre for Susceptibility Testing (NRCST) in Poland in 2014.

Materials and methods

Assessment of the Carba NP and CarbAcineto tests: strain collection and cultivation media

For the initial evaluation of the Carba NP and CarbAcineto tests, a total of 107 strains were used: 81 carbapenemase producers that were well characterised with phenotypic methods, polymerase chain reaction (PCR) and sequencing, and 26 carbapenemase non-producers, including 21 meropenem-non-susceptible strains (Table 1). Both tests were performed by the in-house protocol as previously described [14, 18]. The results presented are those that were recorded after 2 h of incubation time. For cultivation of bacteria, a number of non-selective or screening media and the Mueller–Hinton ready-to-use agar plates, products of six manufacturers, were used (Tables 2 and 3).

Table 1

Isolates used in the Carba NP/CarbAcineto tests evaluation

Species, total number	Carbapenemase genes	No.
Carbapenemase-positive, n = 81
Enterobacteriaceae, n = 34
K. pneumoniae, n = 15	KPC	4
	NDM	5
	VIM	2
	IMP	1
	OXA-48	3
K. oxytoca, n = 3	NDM	1
	VIM	2
E. coli, n = 9	KPC	2
	NDM	4
	OXA-48	3
E. cloacae, n = 5	KPC	1
	NDM	1
	VIM	3
C. freundii, n = 2	KPC	2
Pseudomonas spp., n = 15
P. aeruginosa, n = 9	VIM	8
	IMP	1
P. putida, n = 6	VIM	6
Acinetobacter spp., n = 32
A. baumannii	VIM	6
A. lwoffii	VIM	7
A. junii	VIM	3
A. baumannii	OXA-23	9
A. baumannii	OXA-24/40	6
A. baumannii	OXA-58	1
Carbapenemase-negative, n = 26^a
K. pneumoniae	No	10
P. aeruginosa	No	6
Acinetobacter spp.	No	10

^aOf the 26 carbapenemase-negative isolates, 21 isolates were carbapenem-non-susceptible (8 K. pneumoniae, 6 P. aeruginosa and 7 Acinetobacter spp.)

Table 2

The results of the Carba NP test for Enterobacteriaceae isolates (34 carbapenemase producers and 10 carbapenemase non-producers) cultivated on a set of microbial media

Microbiological media	Manufacturer	VIM; n = 7^a				IMP; n = 1^a		NDM; n = 11^a				KPC; n = 9^a		OXA-48; n = 6^a				c-np^b; n = 10^a
Microbiological media	Manufacturer	+	+/−	−	NG (NI)	+	NG	+	+/−	−	NG (NI)	+	NG	+	+/−	−	NG	+	+/−	−	NG (NI)
Columbia blood agar	BD	7				1		10			(1)	9		6						10
chromID CPS agar	bioMérieux	7				1		11				9		6						10
CHROMagar Orientation Medium	BD	7				1		11				9		6					1	9
Brilliance UTI agar	Oxoid	7				1		11				9		5	1				3	7
Brilliance UTI Clarity agar	Oxoid	7				1		11				9		5	1				3	7
Brilliance ESBL agar	Oxoid	6			(1)	1		10			(1)	9		3		1	2		1	9
chromID ESBL agar	bioMérieux	7				1		11				9		5			1			9	1
Brilliance CRE agar	Oxoid	6			1	1		11				8	1	2	1		3		2	8
chromID CARBA agar	bioMérieux	3	2	2		1		10	1			9		5	1					7	3
KPC CHROM agar	GRASO	7				1		11				9		5		1		2	1	6	1
chromID OXA-48 agar	bioMérieux				7		1	1			10		9	6							10
MH	BD	7				1		10		1		9		6					2	7	(1)
MHE	bioMérieux	7				1		10		1		9		6						8	(2)
MHF	bioMérieux	1		6		1		2	3	6		9		6						10
MH	Oxoid	7				1		11				9		5	1					3	(7)
MH	GRASO	7				1		11				9		6				1		6	(3)
MH	Liofilchem	7				1		10	1			9		6						9	(1)
MH	Bio-Rad	5		2		1		2	3	6		9		6				1	1	8

^a+, positive; +/−, questionable; −, negative; (NI), not interpretable; NG, no growth

^bc-np, carbapenemase-non-producers

Table 3

The Carba NP results for Pseudomonas spp. (15 carbapenemase producers and 6 carbapenemase non-producers) and the CarbAcineto results for Acinetobacter spp. (32 carbapenemase producers and 10 carbapenemase non-producers) grown on a set of microbiological media

		Carba NP										CarbAcineto
		Pseudomonas spp.										Acinetobacter spp.
Microbiological media	Manufacturer	VIM; n = 14^a				IMP; n = 1^a		c-np^b; n = 6^a				VIM; n = 16^a				OXA-like; n = 16^a				c-np^b; n = 10^a
Microbiological media	Manufacturer	+	+/−	−	NG (NI)	+	NG (NI)	+	+/−	−	NG (NI)	+	+/−	−	NG (NI)	+	+/−	−	NG (NI)	+	+/−	−	NG (NI)
Columbia blood agar	BD	14				1				6		16				16						10
chromID CPS agar	bioMérieux	14				1				6		14	2			16						9	(1)
CHROMagar Orientation Medium	BD	13	1			1			2	4		11	4	1		15		1			1	9
Brilliance UTI agar	Oxoid	14				1			3	3		12			4	15		1				9	(1)
Brilliance UTI Clarity agar	Oxoid	12	1		(1)	1		1	2	3		14			2	15	1				1	8	(1)
Brilliance ESBL agar	Oxoid	8	3	2	(1)	1		1		5					13 (3)	13	2		1		1	2	6 (1)
chromID ESBL agar	bioMérieux	12	1	1		1			1	4	1	14	1	1		15	1					8	1 (1)
Brilliance CRE agar	Oxoid	14				1		1	3	2		10	2		4	15	1					7	2 (1)
chromID CARBA agar	bioMérieux	10	1	3		1		1	1	3	1	10			6	15	1					8	2
KPC CHROM agar	GRASO	12		2		1				6		11	2	3		15		1				8	2
chromID OXA-48 agar	bioMérieux	3		3	8		1			3	3		1	9	6	9	2	4	1			3	7
MH	Bio-Rad	9	5			1		1		5		16				16				1	1	8
MH	Liofilchem	13	1			1			1	5		16				14	1	1				10
MH	GRASO	13	1			1				6		16				16					1	8	(1)
MH	BD	14				1				6		16				15	1			1	2	7
MH	Oxoid	13		1		1				6		16				16						10
MHE	bioMérieux	14				1			2	4		16				16						9	(1)
MHF	bioMérieux	5	3	6		1				6		11	3	2		15	1				1	8	(1)

^a+, positive; +/−, questionable; −, negative; (NI), not interpretable; NG, no growth

^bc-np, carbapenemase-non-producers

The Carba NP and CarbAcineto tests in routine reference diagnostics

In the second part of this work, the Carba NP and CarbAcineto tests were implemented into the routine activity of the NRCST, which is responsible for the reference diagnostics and surveillance of carbapenemase-producing Gram-negative pathogens in Poland. Both tests were performed along with the phenylboronic acid disc test [27], double-disc synergy test with EDTA (DDST-EDTA) [28], temocillin disc test [29] for the phenotypic detection of KPCs, MBLs and OXA-48 types, respectively [30], spectrophotometric assay for imipenem hydrolysis [31] and PCR for bla _KPC-, bla _VIM-, bla _IMP-, bla _NDM-, bla _OXA-48-, bla _OXA-23-, bla _OXA-24/40- and bla _OXA-58-like genes [32]. This analysis was done on 1282 isolates in total (Table 4), including 915 Enterobacteriaceae, 309 Pseudomonas spp. and 58 Acinetobacter spp. collected from April to the end of December 2014 in hospitals all over Poland. All these isolates were cultivated only on Columbia blood agar plates.

Table 4

Performance of the Carba NP/CarbAcineto tests in the analysis of 1282 surveillance isolates submitted to the National Reference Centre for Susceptibility Testing (NRCST) from April to December 2014

Enterobacteriaceae (total, n = 915)^a	Pseudomonas spp. (total, n = 309)^a	Acinetobacter spp. (total, n = 58)^a
Carbapenemase-positive, n = 451	Carbapenemase-positive, n = 118	Carbapenemase-positive, n = 54
Carba NP positive, n = 432	Carba NP positive, n = 115	CarbAcineto positive, n = 48
KPC, n = 77	VIM, n = 115	A. baumannii VIM, n = 2
K. pneumoniae, n = 75	P. aeruginosa, n = 111	A. lwoffii VIM, n = 3
E. coli, n = 1	P. putida, n = 4	A. junii VIM, n = 3
E. cloacae, n = 1		A. baumannii OXA-24/40-like, n = 30
NDM, n = 275		A. baumannii OXA-23-like, n = 10
K. pneumoniae, n = 267
E. coli, n = 2
E. cloacae, n = 4
S. marcescens, n = 2
VIM, n = 57
K. pneumoniae, n = 12
E. coli, n = 6
E. cloacae, n = 26
C. freundii, n = 8
S. marcescens, n = 4
K. oxytoca, n = 1
OXA-48, n = 23
K. pneumoniae, n = 7
E. coli, n = 14
E. aerogenes, n = 2
Carba NP questionable, n = 18	Carba NP questionable, n = 3	CarbAcineto questionable, n = 6
K. pneumoniae NDM, n = 14	P. aeruginosa VIM, n = 3	A. baumannii OXA-24/40-like, n = 1
K. pneumoniae OXA-48, n = 1		A. baumannii OXA-23-like, n = 3
E. coli OXA-48, n = 1		A. baumannii OXA-58, n = 2
E. cloacae KPC, n = 1
C. freundii VIM, n = 1
Carba NP not interpretable, n = 1
K. pneumoniae NDM, n = 1
Carbapenemase-negative, n = 464	Carbapenemase-negative, n = 191	Carbapenemase-negative, n = 4
Carba NP negative, n = 433	Carba NP negative, n = 189	CarbAcineto negative, n = 4
Carba NP questionable, n = 30	Carba NP questionable, n = 2
K. pneumoniae, n = 19	P. aeruginosa, n = 2
E. cloacae, n = 9
S. marcescens, n = 1
P. mirabilis, n = 1
Carba NP not interpretable, n = 1
K. pneumoniae, n = 1
Sensitivity 95.8% (95% CI, 93.9–97.6%)	Sensitivity 97.5% (95% CI, 94.6–100%)	Sensitivity 88.9% (95% CI, 80.4–97.4%)
Specificity 93.3% (95% CI, 90.9–95.6%)	Specificity 99.0% (95% CI, 97.6–100%)
PPV 95.8% (95% CI, 93.9–97.6%)	PPV 97.5% (95% CI, 94.6–100%)	PPV 88.9% (95% CI, 80.4–97.4%)
NPV 93.3% (95% CI, 90.9–95.6%)	NPV 99.0% (95% CI, 97.6–100%)

^aPPV, positive predictive value; NPV, negative predictive value; CI, confidence interval

Results

Assessment of the Carba NP and CarbAcineto tests and the cultivation media

For Enterobacteriaceae, the Carba NP test performed well, with the carbapenemase-producing strains cultured on most of the non-selective or screening media (Table 2). False-negative results were obtained only for single isolates with VIMs or OXA-48s grown on three types of chromogenic media. When bacteria were cultivated on Mueller–Hinton (MH) agars, the Carba NP test was positive for all KPC, IMP and all but one OXA-48 producers, while false-negative or questionable results were obtained for NDM- and VIM-producing strains. For a number of carbapenemase-negative strains picked up from some media, the results were questionable and for single strains were false-positive.

The results of the Carba NP test for Pseudomonas spp. strains are presented in Table 3. In the case of carbapenemase (VIM or IMP) producers, the best results were observed for the strains cultivated on the Columbia blood agar, chromID CPS, Brilliance UTI agar (Oxoid) and Brilliance CRE agar (Oxoid). The false-negative results were observed for some isolates cultivated on five other chromogenic media, and on MH (Oxoid) and MHF (bioMérieux) agars. For single carbapenemase-negative strains cultivated on five media, false-positive results were observed.

The results of the CarbAcineto test for Acinetobacter spp. strains are shown in Table 3. As in the case of Enterobacteriaceae and Pseudomonas spp., the impact of the cultivation medium on CarbAcineto was revealed; moreover, for isolates with OXA-like carbapenemases, the correct results were observed more often than for VIM-positive strains (Table 3).

The Carba NP and CarbAcineto tests in routine reference diagnostics

The results of the comparison of the Carba NP/CarbAcineto tests with the standard methodology used by the NRCST, obtained with 1282 bacterial isolates suspected of carbapenemase production, are presented in Table 4. The phenotypic tests and PCRs detected various carbapenemases in 451/915 Enterobacteriaceae, 118/309 Pseudomonas spp. and 54/58 Acinetobacter spp. isolates. For Enterobacteriaceae, the overall sensitivity and positive predictive value (PPV) of Carba NP were 95.8% [95% confidence interval (CI), 93.9–97.6%], and the specificity and negative predictive value (NPV) were 93.3% (95% CI, 90.9–95.6%). For Pseudomonas spp. the sensitivity and PPV were 97.5% (95% CI, 94.6–100%), and the specificity and NPV were 99.0% (95% CI, 97.6–100%). For Acinetobacter spp., the sensitivity and PPV of CarbAcineto were 88.9% (95% CI, 80.4–97.4%).

Discussion

The Carba NP test was described for the first time in 2012 by Nordmann et al. as a rapid, easy and cheap method for carbapenemase detection in Enterobacteriaceae and Pseudomonas spp., with high sensitivity and specificity [1, 15]. In previous studies, the test was evaluated by several groups, often confirming the original observations [2, 19, 33‐35]. However, one study undermined the sensitivity in the case of MBL-producing strains [2]. The problem turned out to be associated with the cultivation medium used [16‐18], and the follow-up study by Dortet et al. documented well the impact of microbiological media on the performance of Carba NP [18].

In the first part of this work, well-characterised Enterobacteriaceae, Pseudomonas spp. and Acinetobacter spp. strains with various carbapenemases were used, along with a broad panel of commercially available media. The results clearly illustrated the influence of the media on the Carba NP/CarbAcineto results. According to our experience, the Columbia blood agar is the best choice for the cultivation of bacteria for the Carba NP/CarbAcineto tests, providing the highest sensitivity and clarity of the results. The VIM or NDM producers harvested from most of the MH agars yielded a remarkable number of false-negative results, which were most probably related to lower zinc ions’ concentrations that is crucial for the MBL activity [18]. Owing to the low incidence of OXA-48 producers in Poland so far, only six such isolates were used in this work, and all of these were clearly positive in Carba NP, in contrast to some other reports [17, 25, 34‐37]. This study has definitely confirmed the usefulness of the CarbAcineto test for the detection of the acquired carbapenemases in Acinetobacter spp. [8, 38, 39] and for distinguishing such isolates from hyperproducers of the natural OXA-51 types and from the carbapenemase-negative carbapenem-non-susceptible isolates, which is important for epidemiological reasons.

The Carba NP and CarbAcineto tests have been used in the NRCST from the end of 2013 and March 2014, respectively, and now are included in its routine algorithm for carbapenemase detection as reliable, inexpensive and easy screening tests, reducing remarkably the time for the first feedback information for clinical laboratories. Based on own experience, and in the context of the alarming spread of carbapenemase-producing Gram-negative pathogens in Poland, the NRCST has been recommending Carba NP/CarbAcineto tests for use in diagnostic microbiology laboratories all over the country.

Acknowledgements

We thank Paweł Urbanowicz for his technical support, and the microbiologists from all the centres sending the isolates to the National Reference Centre for Susceptibility Testing (NRCST) in Poland.

Compliance with ethical standards

Funding

This study was partially financed by the health programme “Narodowy Program Ochrony Antybiotyków na lata 2011–2015” from the Polish Ministry of Health, by the grant SPUB MIKROBANK from the Polish Ministry of Science and Higher Education and by the statutory funding from the Ministry of Science and Higher Education, Poland.

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

The authors declare that ethical approval was not required. The study was conducted using the isolates sent to the NRCST for reference diagnostics.

The authors declare that informed consent was not required.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Unsere Produktempfehlungen

e.Med Interdisziplinär

Kombi-Abonnement

Für Ihren Erfolg in Klinik und Praxis - Die beste Hilfe in Ihrem Arbeitsalltag

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de.

Jetzt testen ¹

e.Med Innere Medizin

Kombi-Abonnement

Mit e.Med Innere Medizin erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes Innere Medizin, den Premium-Inhalten der internistischen Fachzeitschriften, inklusive einer gedruckten internistischen Zeitschrift Ihrer Wahl.

Jetzt testen ²

Nordmann P, Poirel L, Dortet L (2012) Rapid detection of carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis 18:1503–1507. doi:10.3201/eid1809.120355 CrossRefPubMedPubMedCentral

Tijet N, Boyd D, Patel SN, Mulvey MR, Melano RG (2013) Evaluation of the Carba NP test for rapid detection of carbapenemase-producing Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrob Agents Chemother 57:4578–4580. doi:10.1128/AAC.00878-13 CrossRefPubMedPubMedCentral

Dortet L, Poirel L, Nordmann P (2014) Worldwide dissemination of the NDM-type carbapenemases in Gram-negative bacteria. Biomed Res Int 2014:249856. doi:10.1155/2014/249856. ReviewCrossRefPubMedPubMedCentral

Albiger B, Glasner C, Struelens MJ, Grundmann H, Monnet DL; European Survey of Carbapenemase-Producing Enterobacteriaceae (EuSCAPE) working group (2015) Carbapenemase-producing Enterobacteriaceae in Europe: assessment by national experts from 38 countries, May 2015. Euro Surveill 20(45)

Baraniak A, Izdebski R, Fiett J, Gawryszewska I, Bojarska K, Herda M, Literacka E, Żabicka D, Tomczak H, Pewińska N, Szarata M, Ozorowski T, Milner A, Hryniewicz W, Gniadkowski M (2016) NDM-producing Enterobacteriaceae in Poland, 2012–14: inter-regional outbreak of Klebsiella pneumoniae ST11 and sporadic cases. J Antimicrob Chemother 71:85–91. doi:10.1093/jac/dkv282 CrossRefPubMed

Baraniak A, Izdebski R, Fiett J, Herda M, Derde LP, Bonten MJ, Adler A, Carmeli Y, Goossens H, Hryniewicz W, Brun-Buisson C, Gniadkowski M; MOSAR WP2, WP3, and WP5 Study Groups (2015) KPC-like carbapenemase-producing Enterobacteriaceae colonizing patients in Europe and Israel. Antimicrob Agents Chemother 60:1912–1917. doi:10.1128/AAC.02756-15 CrossRefPubMed

Nordmann P, Poirel L (2014) The difficult-to-control spread of carbapenemase producers among Enterobacteriaceae worldwide. Clin Microbiol Infect 20(9):821–830. doi:10.1111/1469-0691.12719. ReviewCrossRefPubMed

Poirel L, Naas T, Nordmann P (2010) Diversity, epidemiology, and genetics of class D β-lactamases. Antimicrob Agents Chemother 54:24–38. doi:10.1128/AAC.01512-08. ReviewCrossRefPubMed

Pitout JD, Nordmann P, Poirel L (2015) Carbapenemase-producing Klebsiella pneumoniae, a key pathogen set for global nosocomial dominance. Antimicrob Agents Chemother 59:5873–5884. doi:10.1128/AAC.01019-15. ReviewCrossRefPubMedPubMedCentral

10.

Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, Paterson DL, Rice LB, Stelling J, Struelens MJ, Vatopoulos A, Weber JT, Monnet DL (2012) Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 18:268–281. doi:10.1111/j.1469-0691.2011.03570.x CrossRefPubMed

11.

Schwaber MJ, Carmeli Y (2008) Carbapenem-resistant Enterobacteriaceae: a potential threat. JAMA 300:2911–2913. doi:10.1001/jama.2008.896 CrossRefPubMed

12.

Munoz-Price LS, Poirel L, Bonomo RA, Schwaber MJ, Daikos GL, Cormican M, Cornaglia G, Garau J, Gniadkowski M, Hayden MK, Kumarasamy K, Livermore DM, Maya JJ, Nordmann P, Patel JB, Paterson DL, Pitout J, Villegas MV, Wang H, Woodford N, Quinn JP (2013) Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis 13:785–796. doi:10.1016/S1473-3099(13)70190-7. ReviewCrossRefPubMedPubMedCentral

13.

Glasner C, Albiger B, Buist G, Tambić Andrasević A, Canton R, Carmeli Y, Friedrich AW, Giske CG, Glupczynski Y, Gniadkowski M, Livermore DM, Nordmann P, Poirel L, Rossolini GM, Seifert H, Vatopoulos A, Walsh T, Woodford N, Donker T, Monnet DL, Grundmann H; European Survey on Carbapenemase-Producing Enterobacteriaceae (EuSCAPE) Working Group (2013) Carbapenemase-producing Enterobacteriaceae in Europe: a survey among national experts from 39 countries, February 2013. Euro Surveill 18. pii: 20525. Erratum in: Euro Surveill 2013;18. pii: 20575. Euro Surveill 2014;19(47): pii=20972

14.

Dortet L, Poirel L, Errera C, Nordmann P (2014) CarbAcineto NP test for rapid detection of carbapenemase-producing Acinetobacter spp. J Clin Microbiol 52:2359–2364. doi:10.1128/JCM.00594-14 CrossRefPubMedPubMedCentral

15.

Dortet L, Poirel L, Nordmann P (2012) Rapid detection of carbapenemase-producing Pseudomonas spp. J Clin Microbiol 50:3773–3776. doi:10.1128/JCM.01597-12 CrossRefPubMedPubMedCentral

16.

Dortet L, Poirel L, Nordmann P (2014) Further proofs of concept for the Carba NP test. Antimicrob Agents Chemother 58:1269. doi:10.1128/AAC.01825-13 CrossRefPubMedPubMedCentral

17.

Tijet N, Boyd D, Patel SN, Mulvey MR, Melano RG (2014) Reply to “further proofs of concept for the Carba NP test”. Antimicrob Agents Chemother 58:1270. doi:10.1128/AAC.02285-13 CrossRefPubMedPubMedCentral

18.

Dortet L, Bréchard L, Poirel L, Nordmann P (2014) Impact of the isolation medium for detection of carbapenemase-producing Enterobacteriaceae using an updated version of the Carba NP test. J Med Microbiol 63:772–776. doi:10.1099/jmm.0.071340-0 CrossRefPubMed

19.

Pires J, Novais A, Peixe L (2013) Blue-carba, an easy biochemical test for detection of diverse carbapenemase producers directly from bacterial cultures. J Clin Microbiol 51:4281–4283. doi:10.1128/JCM.01634-13 CrossRefPubMedPubMedCentral

20.

Bakour S, Garcia V, Loucif L, Brunel JM, Gharout-Sait A, Touati A, Rolain JM (2015) Rapid identification of carbapenemase-producing Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter baumannii using a modified Carba NP test. New Microbes New Infect 7:89–93. doi:10.1016/j.nmni.2015.07.001 CrossRefPubMedPubMedCentral

21.

Pasteran F, Tijet N, Melano RG, Corso A (2015) Simplified protocol for Carba NP test for enhanced detection of carbapenemase producers directly from bacterial cultures. J Clin Microbiol 53:3908–3911. doi:10.1128/JCM.02032-15 CrossRefPubMedPubMedCentral

22.

Poirel L, Nordmann P (2015) Rapidec Carba NP test for rapid detection of carbapenemase producers. J Clin Microbiol 53:3003–3008. doi:10.1128/JCM.00977-15 CrossRefPubMedPubMedCentral

23.

Novais Â, Brilhante M, Pires J, Peixe L (2015) Evaluation of the recently launched Rapid CARB Blue kit for detection of carbapenemase-producing Gram-negative bacteria. J Clin Microbiol 53:3105–3107. doi:10.1128/JCM.01170-15 CrossRefPubMedPubMedCentral

24.

AbdelGhani S, Thomson GK, Snyder JW, Thomson KS (2015) Comparison of the Carba NP, modified Carba NP, and updated Rosco Neo-Rapid Carb kit tests for carbapenemase detection. J Clin Microbiol 53:3539–3542. doi:10.1128/JCM.01631-15 CrossRefPubMedPubMedCentral

25.

Hombach M, von Gunten B, Castelberg C, Bloemberg GV (2015) Evaluation of the Rapidec Carba NP test for detection of carbapenemases in Enterobacteriaceae. J Clin Microbiol 53:3828–3833. doi:10.1128/JCM.02327-15 CrossRefPubMedPubMedCentral

26.

Garg A, Garg J, Upadhyay GC, Agarwal A, Bhattacharjee A (2015) Evaluation of the Rapidec Carba NP test kit for detection of carbapenemase-producing Gram-negative bacteria. Antimicrob Agents Chemother 59:7870–7872. doi:10.1128/AAC.01783-15 CrossRefPubMedPubMedCentral

27.

Doi Y, Potoski BA, Adams-Haduch JM, Sidjabat HE, Pasculle AW, Paterson DL (2008) Simple disk-based method for detection of Klebsiella pneumoniae carbapenemase-type β-lactamase by use of a boronic acid compound. J Clin Microbiol 46:4083–4086. doi:10.1128/JCM.01408-08 CrossRefPubMedPubMedCentral

28.

Lee K, Lim YS, Yong D, Yum JH, Chong Y (2003) Evaluation of the Hodge test and the imipenem-EDTA double-disk synergy test for differentiating metallo-β-lactamase-producing isolates of Pseudomonas spp. and Acinetobacter spp. J Clin Microbiol 41:4623–4629CrossRefPubMedPubMedCentral

29.

van Dijk K, Voets GM, Scharringa J, Voskuil S, Fluit AC, Rottier WC, Leverstein-Van Hall MA, Cohen Stuart JW (2014) A disc diffusion assay for detection of class A, B and OXA-48 carbapenemases in Enterobacteriaceae using phenyl boronic acid, dipicolinic acid and temocillin. Clin Microbiol Infect 20:345–349. doi:10.1111/1469-0691.12322 CrossRefPubMed

30.

European Committee on Antimicrobial Susceptibility Testing (EUCAST) (2013) EUCAST guidelines for detection of resistance mechanisms and specific resistances of clinical and/or epidemiological importance. Version 1.0, December 2013. Available online at: http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Resistance_mechanisms/EUCAST_detection_of_resistance_mechanisms_v1.0_20131211.pdf

31.

Cardoso O, Leitão R, Figueiredo A, Sousa JC, Duarte A, Peixe LV (2002) Metallo-beta-lactamase VIM-2 in clinical isolates of Pseudomonas aeruginosa from Portugal. Microb Drug Resist 8:93–97CrossRefPubMed

32.

Woodford N, Tierno PM Jr, Young JK, Tysall L, Palepou M-FI, Ward E, Painter RE, Suber DF, Shungu D, Silver LL, Inglima K, Kornblum J, Livermore DM (2004) Outbreak of Klebsiella pneumoniae producing a new carbapenem-hydrolyzing class a beta-lactamase, KPC-3, in a New York medical center. Antimicrob Agents Chemother 48:4793–4799CrossRefPubMedPubMedCentral

33.

Vasoo S, Cunningham SA, Kohner PC, Simner PJ, Mandrekar JN, Lolans K, Hayden MK, Patel R (2013) Comparison of a novel, rapid chromogenic biochemical assay, the Carba NP test, with the modified Hodge test for detection of carbapenemase-producing Gram-negative bacilli. J Clin Microbiol 51:3097–3101. doi:10.1128/JCM.00965-13 CrossRefPubMedPubMedCentral

34.

Osterblad M, Hakanen AJ, Jalava J (2014) Evaluation of the Carba NP test for carbapenemase detection. Antimicrob Agents Chemother 58:7553–7556. doi:10.1128/AAC.02761-13 CrossRefPubMedPubMedCentral

35.

Chong PM, McCorrister SJ, Unger MS, Boyd DA, Mulvey MR, Westmacott GR (2015) MALDI-TOF MS detection of carbapenemase activity in clinical isolates of Enterobacteriaceae spp., Pseudomonas aeruginosa, and Acinetobacter baumannii compared against the Carba-NP assay. J Microbiol Methods 111:21–23. doi:10.1016/j.mimet.2015.01.024 CrossRefPubMed

36.

Morey KE, Vega R, Cassidy PM, Buser GL, Rayar JK, Myers JA, Weissman SJ, Beldavs ZG, Pfeiffer CD (2016) Evaluation of the Carba NP Test in Oregon, 2013. Antimicrob Agents Chemother 61. pii: e03005-15. doi:10.1128/AAC.03005-15

37.

Papagiannitsis CC, Študentová V, Izdebski R, Oikonomou O, Pfeifer Y, Petinaki E, Hrabák J (2015) Matrix-assisted laser desorption ionization-time of flight mass spectrometry meropenem hydrolysis assay with NH4HCO3, a reliable tool for direct detection of carbapenemase activity. J Clin Microbiol 53:1731–1735. doi:10.1128/JCM.03094-14 CrossRefPubMedPubMedCentral

38.

Mugnier PD, Poirel L, Naas T, Nordmann P (2010) Worldwide dissemination of the blaOXA-23 carbapenemase gene of Acinetobacter baumannii. Emerg Infect Dis 16:35–40. doi:10.3201/eid1601.090852 CrossRefPubMedPubMedCentral

39.

Izdebski R, Fiett J, Hryniewicz W, Gniadkowski M (2012) Molecular analysis of Acinetobacter baumannii isolates from invasive infections in 2009 in Poland. J Clin Microbiol 50:3813–3815. doi:10.1128/JCM.02271-12 CrossRefPubMedPubMedCentral

Titel: Evaluation of the Carba NP test for carbapenemase detection in Enterobacteriaceae, Pseudomonas spp. and Acinetobacter spp., and its practical use in the routine work of a national reference laboratory for susceptibility testing
verfasst von: E. Literacka
M. Herda
A. Baraniak
D. Żabicka
W. Hryniewicz
A. Skoczyńska
M. Gniadkowski
Publikationsdatum: 25.07.2017
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases / Ausgabe 11/2017
Print ISSN: 0934-9723
Elektronische ISSN: 1435-4373
DOI: https://doi.org/10.1007/s10096-017-3062-0

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

24.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Evaluation of the Carba NP test for carbapenemase detection in Enterobacteriaceae, Pseudomonas spp. and Acinetobacter spp., and its practical use in the routine work of a national reference laboratory for susceptibility testing

Abstract

Introduction

Materials and methods

Assessment of the Carba NP and CarbAcineto tests: strain collection and cultivation media

The Carba NP and CarbAcineto tests in routine reference diagnostics

Results

Assessment of the Carba NP and CarbAcineto tests and the cultivation media

The Carba NP and CarbAcineto tests in routine reference diagnostics

Discussion

Acknowledgements

Compliance with ethical standards

Funding

Conflict of interest

Ethical approval

Unsere Produktempfehlungen

e.Med Interdisziplinär

e.Med Innere Medizin

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Metformin rückt in den Hintergrund

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

Thrombophiliescreening – Wenn, dann richtig und nur bei therapeutischer Konsequenz

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Update Innere Medizin

Springer Medizin

Abstract

Introduction

Materials and methods

Assessment of the Carba NP and CarbAcineto tests: strain collection and cultivation media

The Carba NP and CarbAcineto tests in routine reference diagnostics

Results

Assessment of the Carba NP and CarbAcineto tests and the cultivation media

The Carba NP and CarbAcineto tests in routine reference diagnostics

Discussion

Acknowledgements

Compliance with ethical standards

Funding

Conflict of interest

Ethical approval

Informed consent

Unsere Produktempfehlungen

e.Med Interdisziplinär

e.Med Innere Medizin

Weitere Artikel der Ausgabe 11/2017

Molecular characterization of intestinal carriage of carbapenem-resistant Enterobacteriaceae among inpatients at two Iranian university hospitals: first report of co-production of bla NDM-7 and bla OXA-48

Impact of appropriateness of empiric therapy on outcomes in community-onset bacteremia by extended-spectrum-β-lactamase producing Escherichia coli and Klebisella pneumoniae definitively treated with carbapenems

Development of a peptide ELISA to discriminate vaccine-induced immunity from natural infection of hepatitis A virus in a phase IV study

High-touch surfaces: microbial neighbours at hand

Clinical and microbiological profile of chronic Burkholderia cepacia complex infections in a cystic fibrosis reference hospital in Brazil

Erratum to: Changes in the pneumococcal disease-related hospitalisations in Spain after the replacement of 7-valent by 13-valent conjugate vaccine

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Metformin rückt in den Hintergrund

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

Thrombophiliescreening – Wenn, dann richtig und nur bei therapeutischer Konsequenz

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Update Innere Medizin